Prot #CAB-201-002: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/24 → 12/31/24

Funding

  • Advanced Clinical LLC (Advance Account // Advance Account)
  • Cabaletta Bio, Inc. (Advance Account // Advance Account)